Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Pedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaPedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie
Zmień bibliotekę

Wyszukujesz frazę "Constantine, A." wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-8 z 8
    Tytuł:
    Monotreme nature of the Australian Early Cretaceous mammal Teinolophos
    Autorzy:
    Rich, T H
    Vickers-Rich, P.
    Trusler, P.
    Flannery, T.F.
    Cifelli, R.
    Constantine, A.
    Kool, L.
    Van Klaveren, N.
    Tematy:
    Early Cretaceous
    holotype
    Australia
    mammal
    Teinolophos trusleri
    Cretaceous
    Teinolophos
    Steropodontidae
    paleontology
    Pokaż więcej
    Wydawca:
    Polska Akademia Nauk. Instytut Paleobiologii PAN
    Powiązania:
    https://bibliotekanauki.pl/articles/22297.pdf  Link otwiera się w nowym oknie
    Opis:
    The morphology of the single preserved molar of the holotype of the Australian Early Cretaceous (Aptian) mammal Teinolophos trusleri shows that it is a monotreme and probably a steropodontid, rather than a 'eupantothere' as originally proposed. The structure of the rear of the jaw of T. trusleri supports the molecular evidence that previously formed the sole basis for recognising the Steropodontidae as a distinct family.
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
    Autorzy:
    Dimopoulos, Meletios A.
    Ji, Meng
    D'Sa, Shirley
    Cohen, Aileen
    Xu, Wei
    Tam, Constantine S
    Huang, Jane
    Garcia-Sanz, Ramon
    Roberts, Andrew W
    Zhu, Jun
    Li, Jianyong
    Marlton, Paula
    Guo, Haiyi
    Song, Yuqin
    Jurczak, Wojciech
    Gottlieb, David J
    Zhou, Lei
    Munoz, Javier
    Du, Chenmu
    Phillips, Tycel
    Novotny, William
    Cull, Gavin
    Owen, Roger G.
    Zhu, Hongjie
    Tedeschi, Alessandra
    Trotman, Judith
    Chan, Wai Y.
    Qiu, Lugui
    Opat, Stephen
    Opis:
    Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and identify treatment-limiting toxicities. Data were pooled from 6 studies (N=779). Assessments included type, incidence, severity, and outcome of TEAEs. Median age was 65 years; 20% were ≥75 years old. Most patients had Waldenström macroglobulinemia (33%), chronic lymphocytic leukemia/small lymphocytic lymphoma (29%), or mantle-cell lymphoma (19%). Median treatment duration was 26 months (range: 0.1-65); 16% of patients were treated for ≥3 years. Common nonhematologic TEAEs were upper respiratory tract infection (URI, 39%), rash (27%), bruising (25%), musculoskeletal pain (24%), diarrhea (23%), cough, pneumonia (21% each), urinary tract infection (UTI), fatigue (15% each). Most common grade ≥3 TEAEs were pneumonia (11%), hypertension (5%), URI, UTI, sepsis, diarrhea, and musculoskeletal pain (2% each). Atrial fibrillation and major hemorrhage occurred in 3% and 4% of patients, respectively. Atrial fibrillation, hypertension and diarrhea occurred at lower rates than those reported historically for ibrutinib. Grade ≥3 AEs included neutropenia (23%), thrombocytopenia (8%), and anemia (8%). Serious TEAEs included pneumonia (11%), sepsis (2%), and pyrexia (2%). Treatment discontinuations and dose reductions for AEs occurred in 10% and 8% of patients, respectively. Thirty-nine patients (4%) had fatal TEAEs, including pneumonia (n=9), sepsis (n=4), unspecified cause (n=4), and multiple organ dysfunction syndrome (n=5). This analysis demonstrates that zanubrutinib is generally well tolerated with a safety profile consistent with known BTK inhibitor toxicities; these were manageable and mostly reversible.
    Dostawca treści:
    Repozytorium Uniwersytetu Jagiellońskiego
    Artykuł
    Tytuł:
    Zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia : final analysis from the randomized phase III ASPEN study
    Autorzy:
    Dimopoulos, Meletios A.
    McCarthy, Helen
    Trneny, Marek
    D'Sa, Shirley
    Cohen, Aileen
    Motta, Marina
    Mulligan, Stephen
    Wahlin, Bjorn E.
    Schneider, Jingjing
    Tam, Constantine S.
    Fernández de Larrea, Carlos
    Garcia-Sanz, Ramon
    Allewelt, Heather
    Buske, Christian
    Czyz, Jaroslaw
    Marlton, Paula
    Libby, Edward
    Tani, Monica
    Jurczak, Wojciech
    Opat, Stephen
    Siddiqi, Tanya
    Patel, Sheel
    Cull, Gavin
    Owen, Roger G.
    Leblond, Veronique
    Belada, David
    Castillo, Jorge J.
    Tedeschi, Alessandra
    Treon, Steven P.
    Trotman, Judith
    Chan, Wai Y.
    Lee, Hui-Peng
    Minnema, Monique C.
    Matous, Jeffrey
    Opis:
    The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN. The primary end point was the sum of very good partial response (VGPR) + complete response (CR) rates; secondary and exploratory end points were also reported. Cohort 1 comprised 201 patients (myeloid differentiation primary response 88–mutant WM: 102 receiving zanubrutinib; 99 receiving ibrutinib); cohort 2 comprised 28 patients (myeloid differentiation primary response 88 wild-type WM: 28 zanubrutinib; 26 efficacy evaluable). At 44.4-month median follow-up, VGPR + CR rates were 36.3% with zanubrutinib versus 25.3% with ibrutinib in cohort 1 and 30.8% with one CR in cohort 2. In patients with CXC motif chemokine receptor 4 mutation, VGPR + CR rates were 21.2% with zanubrutinib versus 10.0% with ibrutinib (cohort 1). Median progression-free survival and overall survival were not reached. Any-grade adverse events (AEs) of diarrhea (34.7% v 22.8%), muscle spasms (28.6% v 11.9%), hypertension (25.5% v 14.9%), atrial fibrillation/flutter (23.5% v 7.9%), and pneumonia (18.4% v 5.0%) were more common with ibrutinib versus zanubrutinib; neutropenia (20.4% v 34.7%) was less common with ibrutinib versus zanubrutinib (cohort 1). Zanubrutinib was associated with lower risk of AE-related treatment discontinuation. Overall, these findings confirm the long-term response quality and tolerability associated with zanubrutinib.
    Dostawca treści:
    Repozytorium Uniwersytetu Jagiellońskiego
    Artykuł
      Wyświetlanie 1-8 z 8

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies